Reports from the National Heart, Lung, and Blood Institute-funded Pediatric Cardiomyopathy Registry (PCMR) have shown that dilated cardiomyopathy (DCM) is diagnosed in 0.57 of every 100,000 children per year in the United States and has a 5-year risk of death or heart transplantation of 46%. These results are consistent with those from pediatric cohort studies in Australia and Finland.

In adults, DCM occurs mainly secondary to coronary artery disease. In children, DCM has a wide spectrum of causes: myocarditis, neuromuscular disease, inborn errors of metabolism, malformation syndromes, familial dilated cardiomyopathy (FDCM) and secondary forms caused by dilatation.

Background—Research comparing the survival of children with familial dilated cardiomyopathy (FDCM) to that of children with idiopathic dilated cardiomyopathy (IDCM) has produced conflicting results.

Methods and Results—we analyzed data from children with FDCM or IDCM using the National Heart, Lung, and Blood Institute-funded Pediatric Cardiomyopathy Registry. Compared to children with IDCM (n=647), children with FDCM (n=223) were older (mean 6.2 versus 4.5 years, P<0.001), less often had heart failure (64% versus 78%, P<0.001), had less-depressed mean left ventricular fractional shortening z scores (−7.85±3.98 versus −9.06±3.89, P<0.001) and lower end-diastolic dimension z scores (4.12±2.61 versus 4.91±2.57, P<0.001) at diagnosis. The cumulative incidence of death was lower for patients with FDCM compared with IDCM (P=0.04; hazard ratio 0.64, P=0.06), but no difference in risk of transplant or the combined death or transplant outcome. There was no difference in the proportion of children with echocardiographic normalization at 3 years of follow-up (FDCM, 30% versus IDCM, 26%; P=0.33). Multivariable analysis showed no difference in outcomes between FDCM and IDCM but for both groups older age, congestive heart failure, and increased left ventricular end-systolic dimension z score at diagnosis were independently associated with an increased risk of death or heart transplantation (all Ps<0.001).

Conclusions—There was no survival difference between FDCM and IDCM after adjustment for other factors. Older age, congestive heart failure, and greater left ventricular dilation at diagnosis were independently associated with increased risk of the combined end point of death or transplantation.

Clinical Trial Registration—URL: https://clinicaltrials.gov. Unique identifier: NCT00005391

Key Words: dilatation ■ dilated cardiomyopathy ■ genetics ■ incidence ■ family history ■ pediatrics
environmental or therapeutic exposures, endocrine disease, although nearly 70% of cases are categorized as idiopathic.

Over the past 30 years, outcomes of children with cardiomyopathy have improved little and only by the introduction of heart transplantation. In a previous study, Towbin et al found that the 5-year survival of children with DCM varied depending on cause, with the best clinical outcomes observed in children with FDCM (94%), and the worst in children with neuromuscular disorders (57%). Survival of children with idiopathic disease and malformation syndromes was intermediate (76% for both). Unfortunately, the same study found that a cause of DCM was identified in only 34% of children, although comprehensive pathogenic testing was not always conducted. Another report from the PCMR, using competing risks analysis, showed that children who had FDCM at the time of diagnosis had a lower death rate but a similar transplant rate at 5 years after diagnosis when compared with idiopathic dilated cardiomyopathy (IDCM).

As previous studies have suggested that outcomes in children with DCM are related to the pathogenesis of DCM, improving the ability to identify the underlying cause of the disease could improve risk estimates and treatment strategies. Knowing the underlying cause of DCM is also a prerequisite for risk assessment for family members. Therefore, we undertook a new PCMR analysis comparing children with FDCM to children with IDCM with a documented negative family history.

We hypothesized that transplant-free survival (absence of death or heart transplantation) at the time of last follow-up would be better in children with FDCM than in those with IDCM. Using data from the PCMR, we also identified and compared the predictors of the combined end point of death or transplant of children with FDCM to those with IDCM.

Methods

The PCMR is a cooperative effort of nearly 100 centers in the United States and Canada that enrolled children with primary cardiomyopathy between January 1990 and February 2009. The PCMR design and implementation are described in detail elsewhere. The study was approved by an institutional review committee and the subjects gave informed consent.

Briefly, children aged <18 years, newly diagnosed with cardiomyopathy at participating centers, were eligible for inclusion. Children were ineligible if they had a specific secondary cause of DCM, such as pulmonary parenchymal or vascular disease, endocrine disease, rheumatic disease, immunologic disease, cardiotoxic exposures, or a congenital cardiovascular malformation, that occurred independently of a malformation syndrome. All participating centers obtained Institutional Review Board approval to enroll patients in the registry.

Demographic and Clinical Characteristics

In analyses, echocardiographic measurements, including LV end-diastolic dimension (LVEDD) and end-systolic dimension, LV end-diastolic posterior wall thickness, end-diastolic septal thickness, and LV mass were expressed as z scores relative to body surface area in normal children; LV fractional shortening (LVFS) and LV ejection fraction (LVEF) were expressed as age-adjusted z scores. Data on the presence of atrial enlargement (left, right, or both), and LVEF were available for less than half of children so were not analyzed further.

Statistical Methods

A Fisher exact test was used to compare the frequencies of categorical variables; Student’s t test (for variables with normal distributions) and the Wilcoxon rank-sum test (for variables with other continuous distributions) were also used to evaluate differences by the presence or absence of FDCM.

The Kaplan–Meier method was used to estimate the incidence of the composite end point of the earliest occurring of pretransplant death and cardiac transplant. The two components of the composite, pretransplant mortality and transplant, were analyzed using cumulative incidence functions, as death is a competing risk to the occurrence of transplant, with the use of Gray’s test for hypothesis testing. Regression modeling to compare the incidence of pretransplant death and the incidence of transplant between the FDCM versus IDCM groups was conducted using the subdistribution hazard model methodology of Fine and Gray. Similarly, the echocardiographic outcomes were analyzed in a competing risks framework with the methodology described above. The component outcomes were echocardiographic normalization, pretransplant death/transplant composite, and persistently abnormal echocardiogram. Echocardiographic normalization was defined as having both LVEDD <2 standard deviations above normal for body surface area (LVEDD z score <2) and LVFS or LVEF <2 standard deviations below normal for age (LVFS or LVEF z score <=2).

Cox proportional hazards regression modeling was used to assess FDCM versus IDCM differences in the composite outcome of death/transplant, and to identify the factors that were variably associated with the composite end point. To determine whether the predictors of death/transplant differed for FDCM and IDCM, each covariate was tested for interaction. Multivariable modeling was used to identify independent predictors of death/transplant. The multivariable model selection procedure included all variables with a univariate P value <0.20, with the exception of medications at diagnosis, left or right atrial enlargement, and ejection fraction because of the large number of missing values for these variables. The procedure to construct appropriate covariate-adjusted models included all variables with an FDCM versus IDCM univariate P value <0.10. However, LVEDD rather than LV end-systolic dimension was used for final models because of missing data in the latter.

Alpha was set at 0.05, and all tests were 2-tailed. Data were analyzed with the Statistical Analysis System statistical software program, version 9.3 (SAS Institute, Cary, NC), the free software package R “cmpsrk” and S-PLUS version 6.1 (Insightful Corporation, Seattle, Washington, DC).
malformation syndromes, and neuromuscular disorders) at follow-up, and 454 children in whom a specific cause (other than FDCM) was identified at clinical presentation. The median follow-up time of patients who did not reach an end point of death or transplantation (nontransplanted survivors) was 3.7 years (interquartile range [IQR]: 1.0–6.9 years) for the FDCM group and 2.1 years (IQR: 0.6–5.1) for the IDCM group. The median follow-up time for the entire cohort across both groups was 2.4 years (IQR: 0.8–5.6).

Children with FDCM were significantly older at presentation than children with IDCM (median, 3.3 years [IQR: 0.3–12.1] versus 1.0 year [IQR: 0.3–9.2]), less likely to have CHF at diagnosis (64.1% versus 78.2%, \( P < 0.001 \)), and more likely to have a family history of sudden death (39.0% versus 2.5%, \( P < 0.001 \); Table 1). Children with FDCM also had significantly lower mean \( z \) scores for LVEDD (\( P = 0.006 \)), and significantly higher mean \( z \) scores for end-diastolic septal thickness (\( P = 0.034 \)), LVFS (\( P < 0.001 \)), and LVEF (\( P = 0.008 \); Table 1). Compared to children with FDCM, children with IDCM were significantly more likely to receive any cardiac medication at diagnosis (95.8% versus 91.4%, \( P = 0.03 \)) and antiarrhythmic therapy (23.5% versus 13.7%, \( P = 0.02 \)).

**Outcomes**

We observed 99 events in the 223 patients with FDCM (22 deaths and 77 transplants) and 296 events in the 647 patients with IDCM (90 deaths and 206 transplants). There was a significant difference in the cumulative incidence of pretransplant mortality; children with FDCM fared better than those with IDCM (Gray test \( P = 0.04 \); Fine–Gray hazard ratio (HR) for pretransplant death 0.64; Figure 1A). The cumulative incidence of pretransplant death at 3 years postcardiomyopathy

### Table 1. Characteristics of Children With Familial Dilated Cardiomyopathy or Idiopathic Dilated Cardiomyopathy

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall</th>
<th>FDCM</th>
<th>IDCM</th>
<th>( P ) Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>n†</td>
<td>870</td>
<td>223</td>
<td>647</td>
<td></td>
</tr>
<tr>
<td><strong>Age at diagnosis</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (standard deviations), y</td>
<td>4.9 (5.9)</td>
<td>6.2 (6.4)</td>
<td>4.5 (5.8)</td>
<td>0.001</td>
</tr>
<tr>
<td>Median (IQR), y</td>
<td>1.2 (0.3–10.3)</td>
<td>3.3 (0.3–12.1)</td>
<td>1.0 (0.3–9.2)</td>
<td>0.04</td>
</tr>
<tr>
<td>Age &lt;1 y at diagnosis, %</td>
<td>47.4</td>
<td>42.2</td>
<td>49.2</td>
<td>0.07</td>
</tr>
<tr>
<td>Male, %</td>
<td>50.6</td>
<td>54.7</td>
<td>49.1</td>
<td>0.16</td>
</tr>
<tr>
<td>Race/ethnicity, %</td>
<td></td>
<td></td>
<td></td>
<td>0.06</td>
</tr>
<tr>
<td>White</td>
<td>54.2</td>
<td>60.1</td>
<td>52.2</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>21.2</td>
<td>16.1</td>
<td>23.0</td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>17.3</td>
<td>15.1</td>
<td>18.0</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>7.3</td>
<td>8.7</td>
<td>6.8</td>
<td></td>
</tr>
<tr>
<td>Congestive heart failure at diagnosis, %</td>
<td>74.6</td>
<td>64.1</td>
<td>78.2</td>
<td>(&lt; 0.001)</td>
</tr>
<tr>
<td>Family history of sudden death, % (total n)</td>
<td>10.5 (727)</td>
<td>39.0 (159)</td>
<td>2.5 (568)</td>
<td>(&lt; 0.001)</td>
</tr>
<tr>
<td><strong>Left ventricular echocardiographic z scores, mean (standard deviations)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>End-diastolic dimension (total n=699, 175, and 524)</td>
<td>4.71 (2.60)</td>
<td>4.12 (2.61)</td>
<td>4.91 (2.57)</td>
<td>(&lt; 0.001)</td>
</tr>
<tr>
<td>End-systolic dimension (total n=614, 160, and 454)</td>
<td>6.35 (3.00)</td>
<td>5.79 (2.89)</td>
<td>6.55 (3.01)</td>
<td>0.006</td>
</tr>
<tr>
<td>Fractional shortening (total n=713, 183, and 530)</td>
<td>−8.74 (3.95)</td>
<td>−7.85 (3.98)</td>
<td>−9.06 (3.89)</td>
<td>(&lt; 0.001)</td>
</tr>
<tr>
<td>End-diastolic posterior wall thickness (total n=553, 145, and 408)</td>
<td>−0.60 (2.58)</td>
<td>−0.63 (2.66)</td>
<td>−0.59 (2.56)</td>
<td>0.86</td>
</tr>
<tr>
<td>End-diastolic septal thickness (total n=515, 126, and 389)</td>
<td>−0.98 (1.92)</td>
<td>−0.67 (1.99)</td>
<td>−1.09 (1.88)</td>
<td>0.03</td>
</tr>
<tr>
<td>Mass (total n=545, 143, and 402)</td>
<td>2.49 (2.78)</td>
<td>2.32 (3.08)</td>
<td>2.55 (2.67)</td>
<td>0.43</td>
</tr>
<tr>
<td><strong>Medications at diagnosis (n)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any cardiac medication</td>
<td>94.7% (786)</td>
<td>91.4% (198)</td>
<td>95.8% (588)</td>
<td>0.03</td>
</tr>
<tr>
<td>Anticongestive therapy‡</td>
<td>86% (843)</td>
<td>82.2% (213)</td>
<td>87.3% (630)</td>
<td>0.07</td>
</tr>
<tr>
<td>Antiarrhythmic therapy</td>
<td>20.6% (462)</td>
<td>13.7% (139)</td>
<td>23.5% (323)</td>
<td>0.02</td>
</tr>
<tr>
<td>Angiotensin-converting enzyme inhibitor</td>
<td>62.7% (461)</td>
<td>60.9% (138)</td>
<td>63.5% (323)</td>
<td>0.60</td>
</tr>
<tr>
<td>β-blocker</td>
<td>13.2% (461)</td>
<td>15.1% (139)</td>
<td>12.4% (322)</td>
<td>0.46</td>
</tr>
<tr>
<td>Carnitine</td>
<td>1.5% (461)</td>
<td>0.7% (139)</td>
<td>1.9% (322)</td>
<td>0.68</td>
</tr>
</tbody>
</table>

FDCM indicates familial dilated cardiomyopathy; IDCM, idiopathic dilated cardiomyopathy; and IQR, interquartile range.

*\( P \) values compare the differences between FDCM and IDCM.

†Sample size is smaller than the total stated for selected variables (family history; left ventricular mass).

‡Anticongestive therapy is defined as digoxin or diuretics.
was 8.8% (95% confidence interval [CI], 5.4%–13.2%) and 14.6% (95% CI, 11.8%–17.8%) in the FDCM and IDCM groups, respectively. However, the HR for pretransplant death in the FDCM versus IDCM groups after adjustment for the presence of CHF at diagnosis did not differ from one (HR, 0.71; 95% CI, 0.44–1.13; \( P = 0.14 \); Table 2).

There was no significant difference in the cumulative incidence of transplant (\( P = 0.72 \), Figure 1B), nor for the distributions for time to the composite outcome of death/transplant (\( P = 0.15 \), Figure 2). The cumulative incidence of transplant at 3 years with pretransplant death as competing risk were 34.2% (95% CI, 27.5%–41.0%) and 36.1% (95% CI, 32.1%–40.3%) in the FDCM and IDCM groups, respectively (\( P = 0.997 \)). In covariate-adjusted models for the separate outcomes of pretransplant death and transplantation, there remained no difference between the FDCM and IDCM groups (Table 2).

At three years after diagnosis of cardiomyopathy, there was no difference in the proportion of children with echocardiographic normalization between patients with FDCM and those with IDCM (\( P = 0.33 \). The rates were 30% versus 26%, respectively, at 3 years. We found no differences in medical therapy between the children with echo normalization and those without for both the IDCM and FDCM groups except that children with FDCM who did not have echo normalization were significantly more likely to receive anticongestive therapies (\( P < 0.001 \)).

**Risk Factors for Death/Transplant**

Since there were no differences in time to death or transplant between FDCM and IDCM groups, we combined the groups and identified univariate risk factors for the composite outcome of time to death or transplantation since diagnosis (Table 3). The risk of death or transplant was associated with older age at diagnosis (HR, 1.03; 95% CI, 1.01%–1.05%). Diagnosis after 1 year of age significantly increased the risk of death or transplant by nearly 40% (HR, 1.39; 95% CI, 1.14%–1.70%). The HR for death or transplant was 3.18× as large for children with CHF at diagnosis as it was for those without (Table 3). For the subset of children with medication class data, antiarrhythmic use was associated with death/transplant (HR, 1.73; 95% CI, 1.22%–2.46%). We identified an interaction (\( P = 0.025 \)) between DCM type (FDCM versus IDCM) and only one clinical factor: LVEDD \( z \) score. More abnormal dilation was a significant risk factor for both groups, but the effect was stronger for children with FDCM (HR, 1.24; 95% CI, 1.14%–1.35% in FDCM versus HR, 1.10; 95% CI, 1.05%–1.16% in IDCM). However, for the entire cohort the only independent predictors of death/transplant were those shown in the multivariable model in Table 2 (LVEDD \( z \) score without an interaction, CHF and older age at diagnosis).

**Discussion**

The study analyzes outcome and risk factors in patients with FDCM and DCM. The major finding is that the risk factors for the composite outcome of death or transplant are CHF and older age at diagnosis, particularly age at presentation older than 1 year increased the risk of death or transplant by almost 40%; dilatation of the LV (LVEDD \( z \) score) was also a significant risk factor for death or transplant. In the subsets of children with medications data available, we found that antiarrhythmic use was associated with an increase of death or transplant; this finding may reflect the fact that patients were sicker although the possibility of a proarrhythmic effect cannot be excluded and caution should be used when starting these drugs. Our findings show that the pathogenesis of cardiomyopathy, FDCM, or IDCM was not a factor in determining the outcome; patient clinical characteristics are the major determinant.
Although there was no difference in outcome between the FDCM and IDCM groups, we found that children with FDCM were significantly older at the time of diagnosis, less likely to present with heart failure, and more likely to have a positive family history of sudden cardiac death than were children with IDCM. In addition, they showed less evidence of pathological LV remodeling at presentation as shown by significantly less, but still abnormal, LV dilation, less septal thinning, and better, but still abnormal, LV function (LVFS or LVEF). Children with IDCM were more likely to be on cardiac medications and antiarrhythmic at diagnosis probably reflecting the fact that IDCM children were sicker at presentation as evidence that they were more likely to present with CHF.

Of children with either FDCM or IDCM, 26% to 30% experienced echocardiographic normalization over time, a finding consistent with normalization rates in a previous PCMR analysis of all patients with IDCM (regardless of family history).14

Our report represents perhaps the largest study to date in children comparing clinical outcomes in FDCM and IDCM. In previous studies of patients with IDCM, further investigation of relatives found that between 20% and 50% of index cases had FDCM.15–18 Although these studies were mostly of adults, they all included pediatric cases of DCM. In our study, of the 1832 cases of pure DCM in the PCMR database, 12% of children had a diagnosis of FDCM at their most recent follow-up. Similarly, in the National Australian Childhood Cardiomyopathy Study, the prevalence of FDCM in children aged <10 years was 14.7%.3

Clear clinical or echocardiographic markers that differentiate FDCM from IDCM have been difficult to identify. FDCM cannot be reliably diagnosed in any

![Figure 2](http://circheartfailure.ahajournals.org/)

**Figure 2.** Kaplan–Meier curve comparing time to death and transplantation between children with familial dilated cardiomyopathy (FDCM) and idiopathic cardiomyopathy without a family history of cardiomyopathy (IDCM). Log-rank $P=0.15$; 395 events.
individual child based solely on clinical (other than family history) or echocardiographic data, a finding consistent with other reports. Even an accurate family history cannot necessarily identify FDCM at the time of diagnosis. Indeed, as illustrated by the PCMR experience, it is likely that a subset of the patients categorized as IDCM will be subsequently determined to have FDCM because of the manifestation of the disease in relatives at a later time and others may carry the same causative gene mutations despite the absence of a previous family history of DCM. Presently, the diagnosis of FDCM requires assembling a complete and accurate family history, as well as screening family members with echocardiography or another imaging modality. A recent review concluded that proper screening of family members with echocardiography or other assessments of LV size and function will detect FDCM in 20% to 35% of patients with IDCM. Genetic evaluation of these populations using newly available DCM genetic testing panels should improve identification of children with FDCM. Because most cases of IDCM are suspected to have a genetic cause, evaluation of these children with clinically available DCM genetic testing panels is also important.

For many years, genetic testing for DCM in children has been used infrequently in clinical practice because of the high cost with traditional sequencing methods and the relatively low probability of identifying a mutation in one of the many DCM genes. However, large gene panels are now available as a result of the development of next-generation sequencing approaches which can screen a larger number of genes simultaneously at lower cost and also result in a higher number of positive results. Thus, incorporating genetic testing and genetic counseling into the care of patients with DCM is recommended. In an Australian prospective study of sudden cardiac death in children and young adults, the authors showed that genetic testing performed at autopsy was able to identify a likely cause of death in 27% of the cases of unexplained sudden cardiac death. Although the cost-effectiveness of genetic testing in DCM has not yet been evaluated, studies on the cost-effectiveness of genetic testing in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and long QT syndrome indicate an overall benefit over screening via cardiac surveillance.

### Strengths and Limitations of the Study

The PCMR is the largest longitudinal study of cardiomyopathy in children, including more than 3,500 affected children. However, the diagnosis of FDCM or evidence of affected family members in children with IDCM was identified only from the medical record. Specifically, the diagnosis of FDCM was based on a notation of FDCM in the medical record without
any a priori PCMR requirement for data on detailed pedigrees or from comprehensive genetic testing (which has evolved considerably over the life of the PCMR) to establish a diagnosis of FDCM. It is important to note that family history is dynamic and needs to be revisited at each clinical encounter since children initially diagnosed as IDCVM, may later be categorized as FDCM, given their updated family history or new genetic testing data. Related to this approach for identifying FDCM, it is possible that the patients in the FDCM group seem to have better survival than IDCVM because longer follow-up allows more opportunity to be classified as FDCM. Furthermore, screening echocardiograms of family members were not available. Medication class was only available for a subset of patients. Almost 30% of the IDCVM cases in the PCMR could not be used in the analysis as a result of inconclusive family histories. Determining whether a patient has familial disease is often difficult, and there is evidence that correct classification requires consistent and ongoing echocardiographic investigation of relatives, who may present with DCM at various ages.\textsuperscript{17,18} Finally, we found no statistically significant difference in the time to death/transplant (43% versus 51% for FDCM versus IDCVM at 3 years). This difference may be considered clinically significant, but we had limited statistical power because of the shorter follow-up time in the IDCVM group.

Echocardiographic screening of relatives has shown that relying on family history alone to identify FDCM may not identify asymptomatic family members with cardiomyopathy or detect whether relatives reported to have DCM actually have had other cardiac diseases.\textsuperscript{29} Because our study relied solely on the family history found in the medical record to make the diagnosis of FDCM, some children may have been misclassified with respect to final DCM category. Changes in clinical protocols addressing the acquisition and documentation of complete pedigrees and comprehensive family screening in this population during the course of this study could also have affected the percentage of children classified as FDCM.

Future Directions

Nearly half of our FDCM cases were not identified as such at their initial clinical presentation. Our findings suggest that at least the first-degree relatives of children presenting with DCM without a clear nonfamilial cause should undergo echocardiographic screening. In addition, state-of-the-art clinical genetic testing of the proband, and if positive, of other family members, should be used to more accurately make the diagnosis of FDCM in the affected child. Advances in clinical genetic testing for DCM, including the development of more comprehensive panels and cost-effective whole-genomic analysis, will eventually provide a more rapid and definitive diagnosis of FDCM in children.

Conclusions

At diagnosis in both FDCM and IDCVM, older age, the presence of CHF, and increased LV dilation are independently associated with poor outcomes. At the time of diagnosis, children eventually categorized as FDCM seem to be at an earlier stage of the disease with less LV remodeling, and a lower prevalence of heart failure, when compared with children with IDCVM.

In summary, recognition of FDCM is important about the implications for screening other family members, but not for the management of the affected individual, as the outcomes are related to patient factors, not whether the child has FDCM or IDCVM.

Acknowledgments

The authors thank the Children’s Cardiomyopathy Foundation for its ongoing and consistent support for the work of the PCMR.

Sources of Funding

The PCMR is supported by grants from the National Heart, Lung, and Blood Institute (R01 HL53392, R01 HL111459, R01 HL109090; Dr Lipshultz, Principal Investigator) and the Children’s Cardiomyopathy Foundation. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the NHLBI.

Disclosures

None.

References

Our report represents perhaps the largest study to date comparing clinical outcomes in familial dilated cardiomyopathy (FDCM) and idiopathic dilated cardiomyopathy (IDCM) in children. We found that children with FDCM were significantly older at the time of diagnosis, less likely to present with heart failure, and more likely to have a positive family history of sudden cardiac death than were children with IDCM. We found no covariate-adjusted difference between the FDCM and IDCM groups in time to death, transplant, or the combined end point of death/transplantation. They also had less evidence of pathologial left ventricular (LV) remodeling at presentation as shown by significantly less, but still highly abnormal, LV dilation, less septal thinning, and better, but still highly abnormal, LV function (LV fractional shortening or LV ejection fraction). Our findings suggest that at least the first-degree relatives of children presenting with DCM without a clear nonfamilial cause should undergo echocardiographic screening. In addition, state-of-the-art clinical genetic testing of both the proband, and if positive, of other family members, should be used to more accurately make the diagnosis of FDCM in the affected child. Advances in clinical genetic testing for DCM, including the development of more comprehensive genetic testing panels and cost-effective whole-genomic analysis, will eventually provide a more rapid and definitive diagnosis of FDCM in children. Because most cases of IDCM are suspected to have a genetic cause, evaluation of these children with clinical available DCM genetic testing panels is also important. In summary, recognition of FDCM is important regarding the implications for screening other family members, but not for the management of the affected individual, since the outcomes are related to patient factors, not whether the child has FDCM or IDCM.
Differences in Presentation and Outcomes Between Children With Familial Dilated Cardiomyopathy and Children With Idiopathic Dilated Cardiomyopathy: A Report From the Pediatric Cardiomyopathy Registry Study Group

Paolo Rusconi, James D. Wilkinson, Lynn A. Sleeper, Minmin Lu, Gerald F. Cox, Jeffrey A. Towbin, Steven D. Colan, Steven A. Webber, Charles E. Canter, Stephanie M. Ware, Daphne T. Hsu, Wendy K. Chung, John L. Jefferies, Christina Cordero and Steven E. Lipshultz for the Pediatric Cardiomyopathy Registry Investigators

_Circ Heart Fail._ 2017;10:
doi: 10.1161/CIRCHEARTFAILURE.115.002637

_Circulation: Heart Failure_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2017 American Heart Association, Inc. All rights reserved.

Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://circheartfailure.ahajournals.org/content/10/2/e002637

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Heart Failure_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Heart Failure_ is online at:
http://circheartfailure.ahajournals.org//subscriptions/